Related Experiment Video
Updated: Jan 13, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Characteristics and Outcomes of Finnish Patients with Waldenström Macroglobulinemia-A Real-World Study
Eleonora Mäkelä1, Johanna Vikkula2, Essi Havula2
1Janssen-Cilag Oy, Espoo, Finland.
Introduction:
Waldenström macroglobulinemia (WM) is a rare, slow-growing B-cell lymphoma characterized by the proliferation of lymphoplasmacytic cells in the bone marrow. WM has been difficult to diagnose and treat. However, recent advances in diagnostics, including the discovery of MYD88 and CXCR4 mutations, and in treatment, including targeted, patient-tolerable therapeutic options in often elderly patients, have together improved the clinical outcomes.
Methods:
In this nationwide retrospective real-world evidence (RWE) study, we report the incidence, prevalence, patient characteristics, comorbidities, overall survival, causes of deaths and healthcare resource utilization (HCRU) of all Finnish patients diagnosed with WM during 2007-2021.
Results:
The mean incidence was 0.49, age standardized incidence 0.23 and prevalence (in 2021) 3.7 per 100,000 people. The median overall survival (mOS) for all WM patients during the entire study period was 7.3 years. An improvement in the OS was observed over time (2007-2014 vs. 2015-2021 cohorts). Infections along with WM itself were a major cause of death among WM patients.
Conclusions:
To our knowledge, this is the first RWE study of WM patients in Finland.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
